Melatonin pharmacokinetics and dose extrapolation after enteral infusion in neonates subjected to hypothermia. Issue 4 (18th March 2019)

• Record Type: Journal Article
• Authors: Balduini, Walter; Weiss, Michael D.; Carloni, Silvia; Rocchi, Marco; Sura, Livia; Rossignol, Candace; Longini, Mariangela; Bazzini, Francesco; Perrone, Serafina; Ott, Deborah; Wadhawan, Rajan; Buonocore, Giuseppe
• Is Part Of: Journal of pineal research. Volume 66:Issue 4(2019)
• Page Start: n/a
• Page End: n/a
• Publication Date: 2019-03-18
• Subjects: hypothermia -- hypoxic‐ischemic encephalopathy -- immaturity -- infants -- melatonin -- neuroprotection -- pharmacokinetics; Pineal gland -- Periodicals; Pineal Gland -- Periodicals; Épiphyse (Glande); Périodique électronique (Descripteur de forme); Ressource Internet (Descripteur de forme); 612.492
• DOI: 10.1111/jpi.12565
• Languages: English
• ISSNs: 0742-3098

Abstract

Abstract: Introduction: Neonates with hypoxic‐ischemic encephalopathy (HIE) undergoing hypothermia may benefit from adjunctive therapy with melatonin. However, melatonin safety, pharmacokinetics (PK), and dosage in this sensitive population are still unknown. Methods and results: This study assessed the PK and safety of melatonin enteral administration to neonates with HIE undergoing hypothermia. Melatonin was infused at 0.5 mg/kg in five neonates with HIE undergoing hypothermia. Infusion started 1 hour after the neonates reached the target temperature of 33.5°C. Blood samples were collected before and at selective times after melatonin infusion. Abdominal complications or clinically significant changes in patients' vital signs were not found during or after melatonin. The peak plasma concentration reached 0.25 µg/mL. The area under the curve in 24 hours was 4.35 µg/mL*h. Discussion: Melatonin half‐life and clearance were prolonged, and the distribution volume decreased compared to adults. In silico simulation estimated that the steady state can be reached after four infusions. Hypothermia does not affect melatonin PK. In humans high blood concentrations with lower doses can be achieved compared to animal experimentation, although intravenous administration is advised in the neonate population. Our study is a preparatory step for future clinical studies aimed at assessing melatonin efficacy in HIE.